SMS Pharmaceuticals: 38th AGM Rescheduled to Sep 29, Dividend Record Date Sep 22
SMS Pharmaceuticals Limited has rescheduled its 38th AGM to September 29, 2026. The book closure period is from September 23 to September 29, 2026. The record date for dividend eligibility is now September 22, 2026.
Changes to AGM dates, book closure, and record dates can affect shareholder planning and dividend distribution timelines. While not a fundamental business change, it requires attention from investors and stakeholders regarding participation and eligibility for dividends, thus having a medium impact.
The announcement is a rescheduling of corporate events (AGM, book closure, record date) due to administrative reasons. There is no new financial information or strategic development that would positively or negatively impact the company's outlook. Therefore, the sentiment is neutral.
SMS Pharmaceuticals Limited has announced a revised schedule for its 38th Annual General Meeting (AGM), originally set for September 23, 2026. The AGM will now be held on Tuesday, September 29, 2026, via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). This change is due to unavoidable circumstances, administrative, and scheduling constraints.
Consequently, the company has also updated its book closure and record dates. The Register of Members and Share Transfer Books will remain closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026, inclusive, for the purpose of the 38th AGM.
Furthermore, the record date for determining members eligible to receive the dividend for the financial year 2025-26 has been revised to Tuesday, September 22, 2026. The dividend, if approved at the AGM, will be paid within the stipulated time period. All other details from the previous intimation dated July 31, 2026, remain unchanged.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.